Castor announces Frans van Houten, former CEO of Philips, as the company’s new chairman of its Board Of Directors

August 22, 2023 10:00 PM AEST | By EIN Presswire
 Castor announces Frans van Houten, former CEO of Philips, as the company’s new chairman of its Board Of Directors
Image source: EIN Presswire

NEW YORK, N.Y., UNITED STATES, August 22, 2023/EINPresswire.com/ -- Castor, an industry leader in modular, patient-centric, clinical trial technology, today announced the appointment of Frans van Houten as the new Chairman of its Board of Directors. His exceptional leadership experience and extensive industry knowledge in the healthcare and technology industries will be invaluable to Castor as the company continues to pursue its mission to make patient-centric trials possible for everyone, anywhere in the world.

Frans van Houten, recognized worldwide for his tenure as CEO of Philips, contributes a proven track record in business transformation, and technology innovation. During his tenure at Philips, he was responsible for transforming the organization from a diversified conglomerate into a focused health technology solutions company. Aside from his role at Castor, van Houten also serves on the Board of Directors of Novartis, a leading global pharmaceutical company, and acts as a key advisor to private equity companies.

“Efficient clinical trials produce quality data that need to be collected through effective engagement with patients, processed and aggregated, all responsibly in compliance with regulatory requirements,” said van Houten. “I have long shared Castor’s belief that clinical trial cloud technology can do a better job in helping pharmaceutical and biotechnology companies scale and expedite timelines with more data accessibility. By combining clinical trial expertise with modern SAAS technology, we will be able to fix traditionally stodgy clinical trial processes to increase operational efficiencies and reduce human effort at every stage in the clinical trial journey.”

“Being able to work with a renowned captain of industry and thought leader such as Frans is a true privilege. I am excited to work with him to ensure Castor stays ahead of our peers with regards to innovation and growth.” said Derk Arts, MD, PhD, CEO and Founder of Castor. “His expansive expertise in the life science and healthcare informatics industries will not only accelerate our growth as we partner with enterprise pharma, but also ensure we effectively navigate these times of drastic change with the advent of AI in clinical research.”

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture.

Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide.

For more information, visit www.castoredc.com. Follow us on LinkedIn at https://www.linkedin.com/company/castoredc

Laura McLoughlin
Castor
[email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.